Cargando…

“I don’t think people are ready to trust these algorithms at face value”: trust and the use of machine learning algorithms in the diagnosis of rare disease

BACKGROUND: As the use of AI becomes more pervasive, and computerised systems are used in clinical decision-making, the role of trust in, and the trustworthiness of, AI tools will need to be addressed. Using the case of computational phenotyping to support the diagnosis of rare disease in dysmorphol...

Descripción completa

Detalles Bibliográficos
Autores principales: Hallowell, Nina, Badger, Shirlene, Sauerbrei, Aurelia, Nellåker, Christoffer, Kerasidou, Angeliki
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9670402/
https://www.ncbi.nlm.nih.gov/pubmed/36384545
http://dx.doi.org/10.1186/s12910-022-00842-4
_version_ 1784832327402127360
author Hallowell, Nina
Badger, Shirlene
Sauerbrei, Aurelia
Nellåker, Christoffer
Kerasidou, Angeliki
author_facet Hallowell, Nina
Badger, Shirlene
Sauerbrei, Aurelia
Nellåker, Christoffer
Kerasidou, Angeliki
author_sort Hallowell, Nina
collection PubMed
description BACKGROUND: As the use of AI becomes more pervasive, and computerised systems are used in clinical decision-making, the role of trust in, and the trustworthiness of, AI tools will need to be addressed. Using the case of computational phenotyping to support the diagnosis of rare disease in dysmorphology, this paper explores under what conditions we could place trust in medical AI tools, which employ machine learning. METHODS: Semi-structured qualitative interviews (n = 20) with stakeholders (clinical geneticists, data scientists, bioinformaticians, industry and patient support group spokespersons) who design and/or work with computational phenotyping (CP) systems. The method of constant comparison was used to analyse the interview data. RESULTS: Interviewees emphasized the importance of establishing trust in the use of CP technology in identifying rare diseases. Trust was formulated in two interrelated ways in these data. First, interviewees talked about the importance of using CP tools within the context of a trust relationship; arguing that patients will need to trust clinicians who use AI tools and that clinicians will need to trust AI developers, if they are to adopt this technology. Second, they described a need to establish trust in the technology itself, or in the knowledge it provides—epistemic trust. Interviewees suggested CP tools used for the diagnosis of rare diseases might be perceived as more trustworthy if the user is able to vouchsafe for the technology’s reliability and accuracy and the person using/developing them is trusted. CONCLUSION: This study suggests we need to take deliberate and meticulous steps to design reliable or confidence-worthy AI systems for use in healthcare. In addition, we need to devise reliable or confidence-worthy processes that would give rise to reliable systems; these could take the form of RCTs and/or systems of accountability transparency and responsibility that would signify the epistemic trustworthiness of these tools. words 294.
format Online
Article
Text
id pubmed-9670402
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-96704022022-11-18 “I don’t think people are ready to trust these algorithms at face value”: trust and the use of machine learning algorithms in the diagnosis of rare disease Hallowell, Nina Badger, Shirlene Sauerbrei, Aurelia Nellåker, Christoffer Kerasidou, Angeliki BMC Med Ethics Research BACKGROUND: As the use of AI becomes more pervasive, and computerised systems are used in clinical decision-making, the role of trust in, and the trustworthiness of, AI tools will need to be addressed. Using the case of computational phenotyping to support the diagnosis of rare disease in dysmorphology, this paper explores under what conditions we could place trust in medical AI tools, which employ machine learning. METHODS: Semi-structured qualitative interviews (n = 20) with stakeholders (clinical geneticists, data scientists, bioinformaticians, industry and patient support group spokespersons) who design and/or work with computational phenotyping (CP) systems. The method of constant comparison was used to analyse the interview data. RESULTS: Interviewees emphasized the importance of establishing trust in the use of CP technology in identifying rare diseases. Trust was formulated in two interrelated ways in these data. First, interviewees talked about the importance of using CP tools within the context of a trust relationship; arguing that patients will need to trust clinicians who use AI tools and that clinicians will need to trust AI developers, if they are to adopt this technology. Second, they described a need to establish trust in the technology itself, or in the knowledge it provides—epistemic trust. Interviewees suggested CP tools used for the diagnosis of rare diseases might be perceived as more trustworthy if the user is able to vouchsafe for the technology’s reliability and accuracy and the person using/developing them is trusted. CONCLUSION: This study suggests we need to take deliberate and meticulous steps to design reliable or confidence-worthy AI systems for use in healthcare. In addition, we need to devise reliable or confidence-worthy processes that would give rise to reliable systems; these could take the form of RCTs and/or systems of accountability transparency and responsibility that would signify the epistemic trustworthiness of these tools. words 294. BioMed Central 2022-11-16 /pmc/articles/PMC9670402/ /pubmed/36384545 http://dx.doi.org/10.1186/s12910-022-00842-4 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research
Hallowell, Nina
Badger, Shirlene
Sauerbrei, Aurelia
Nellåker, Christoffer
Kerasidou, Angeliki
“I don’t think people are ready to trust these algorithms at face value”: trust and the use of machine learning algorithms in the diagnosis of rare disease
title “I don’t think people are ready to trust these algorithms at face value”: trust and the use of machine learning algorithms in the diagnosis of rare disease
title_full “I don’t think people are ready to trust these algorithms at face value”: trust and the use of machine learning algorithms in the diagnosis of rare disease
title_fullStr “I don’t think people are ready to trust these algorithms at face value”: trust and the use of machine learning algorithms in the diagnosis of rare disease
title_full_unstemmed “I don’t think people are ready to trust these algorithms at face value”: trust and the use of machine learning algorithms in the diagnosis of rare disease
title_short “I don’t think people are ready to trust these algorithms at face value”: trust and the use of machine learning algorithms in the diagnosis of rare disease
title_sort “i don’t think people are ready to trust these algorithms at face value”: trust and the use of machine learning algorithms in the diagnosis of rare disease
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9670402/
https://www.ncbi.nlm.nih.gov/pubmed/36384545
http://dx.doi.org/10.1186/s12910-022-00842-4
work_keys_str_mv AT hallowellnina idontthinkpeoplearereadytotrustthesealgorithmsatfacevaluetrustandtheuseofmachinelearningalgorithmsinthediagnosisofraredisease
AT badgershirlene idontthinkpeoplearereadytotrustthesealgorithmsatfacevaluetrustandtheuseofmachinelearningalgorithmsinthediagnosisofraredisease
AT sauerbreiaurelia idontthinkpeoplearereadytotrustthesealgorithmsatfacevaluetrustandtheuseofmachinelearningalgorithmsinthediagnosisofraredisease
AT nellakerchristoffer idontthinkpeoplearereadytotrustthesealgorithmsatfacevaluetrustandtheuseofmachinelearningalgorithmsinthediagnosisofraredisease
AT kerasidouangeliki idontthinkpeoplearereadytotrustthesealgorithmsatfacevaluetrustandtheuseofmachinelearningalgorithmsinthediagnosisofraredisease